Answers are grounded in this paper and cite their sources.
Key Points WT1 mRNA-electroporated DCs can prevent or delay relapse in 43% of patients with AML in remission after chemotherapy. OS compares favorably with the new survival data from the Swedish Acute Leukemia Registry and correlates with molecular and WT1-specific CD8+ T-cell responses.
No takes yet. Share an insight, caveat, or question.
Anguille et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: